Click Here to Download CV

January 2009


Frederick King Goodwin, M.D.

Born:  April 21, 1936 - Cincinnati, Ohio
Married:  October 19, 1963, to Rosemary P. Goodwin, M.S.W., L.C.S.W. -- three children


B.S. - Georgetown University, 1958 - major in biology and philosophy
Graduate Fellowship in Philosophy, St. Louis University, 1958 to 1959
M.D. - St. Louis University School of Medicine, 1963
NIH Graduate School - ten credits in biochemistry, physiology and radiation safety
Fellow, Washington School of Psychiatry, September 1969 to June 1971


Research Assistant, Laboratory of Clinical Biochemistry, National Heart Institute, NIH - Summers of
1960, 1961, 1962
Mixed Internship in Medicine and Psychiatry, State University of New York, Upstate Medical Center,
Syracuse, New York, 1963 to 1964
Resident in Psychiatry, University of North Carolina, Chapel Hill, North Carolina, 1964 to 1965
Licensed to Practice Medicine in the State of Maryland, License No.: D02195, 1965 to present. License
in Maryland in reciprocation with State of Missouri exam passed in 1963.
Clinical Associate, Adult Psychiatry Branch, National Institute of Mental Health (NIMH), 1965 to 1967
Special Research Fellow, Laboratory of Clinical Biochemistry, National Heart Institute, 1967 to 1968
Private Practice of Psychiatry (part-time), 1967 to present
Chief, Clinical Research Unit, Section on Psychiatry, Laboratory of Clinical Science, NIMH, July 1968 to
June 1973
Chief, Section on Psychiatry, Laboratory of Clinical Science, NIMH, July 1973 to January 1977
Chief, Clinical Psychobiology Branch, NIMH, January 1977 to December 1981
Director, Intramural Research Program, NIMH, January 1982 to June 1988
Administrator, Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA), July 1988 to
February 1992
Director, National Institute of Mental Health, March 1992 to April 1994
Science Advisor to the Director of NIMH, May 1994 to January 1997
Research Professor of Psychiatry, The George Washington University Medical Center, May 1994 to
December 2008
Director, Center on Neuroscience, Medical Progress and Society, The George Washington University
Medical Center, May 1994 to present
Director, Program on Medical Science and Society, Ethics and Public Policy Center, September 1997 to
September 1999
Director, Psychopharmacology Research Center, The George Washington University Medical Center,
November 1997 to present    
Host, The Infinite Mind, a national public radio series, March 1998 to 2008
Clinical Professor of Psychiatry, The George Washington University Medical Center, December 2008 to


Non-governmental Appointments:

Faculty, Washington School of Psychiatry, September 1970 to 1982
Consultant, American Medical Association Council on Drugs, May 1970 to July 1974
Adjunct Professor, The George Washington University School of Medicine, Department of Psychiatry,
July 1972 to 1982
Task Force on Research Training, Council of Medical Education and Career Development, American
Psychiatric Association, July 1973 to July 1974
Peer Review Committee, Washington Psychiatric Society, March 1974 to January 1976
Visiting Professor, Department of Psychiatry, University of Wisconsin School of Medicine, Madison,
Wisconsin, September 1976
Visiting Professor, Department of Psychiatry, Boston University, School of Medicine, Boston,
Massachusetts, December 1976
Supporting Editor, Psychopharmacology, April 1976 to 1979
Editorial Advisory Board, Progress in Neuropsychopharmacology, Pergamon Press, New York, July 1976
to 1992
Editorial Board, Acta Neurologica, September 1977 to 1992
Visiting Professor, Department of Psychiatry, University of California, School of Medicine, Irvine,
California, February 1977
Editorial Board, Archives of General Psychiatry, January 1978 to 1998
Board of Editorial Advisors, Progress in Psychiatric Drug Treatment, Brunner/Mazel, New York
Chairman, Committee on Problems of Public Concern, American College of
Neuropsychopharmacology, January 1979 to December 1983
Founding Co-Editor-in-Chief, Psychiatry Research: International Journal for Rapid Communication,
January 1979 to 1999
Visiting Professor, Department of Psychiatry, University of Southern California School of Medicine,
February 1979
Guest Editor, Special Issue on Lithium, Archives of General Psychiatry, Volume 36, July 20, 1979
Chairman, Committee for the Protection of Human Subjects in Psychiatric Research, American
Psychiatric Association, September 1979 to December 1982
Visiting Professor, Department of Psychiatry, Duke University, School of Medicine, November 1979 to
Board of Scientific Advisors, Max Planck Institute for Psychiatry, Munich, Germany, 1979 to 1985
Nominating Committee, American College of Neuropsychopharmacology, 1979 to 1980
Editorial Board, Journal of Clinical Psychopharmacology, September 1980 to present
Editorial Board, Neuropsychobiology, 1983 to present
Consultant, Council on Research, American Psychiatric Association, May 1983 to 1988
Advisory Board for Clinical Research Training Program, Harvard Medical School, Department of
Psychiatry, Massachusetts Mental Health Center, October 1984 to June 1988
Scientific Advisory Board of the American Friends of Jerusalem Mental Health Center, 1984 (indefinite)
Scientific Council, National Alliance on Mental Illness (formerly National Alliance for the Mentally Ill), 1984
to present
Nominating Committee, American College of Neuropsychopharmacology, 1984 to 1985
Group for the Advancement of Psychiatry (GAP), Committee on Research, 1985
Scientific Council, National Alliance for Research on Schizophrenia and Depression, August 1985 to
National Academy of Sciences’ Committee on Human Rights, November 1985 to present
Editorial Advisory Board, Human Psychopharmacology:  Clinical and Experimental, 1985 to 1988
(3-year initial membership)
Editorial Advisory Board, Journal Club Psychiatry, 1985-1989
Advisory Board of the Pfizer Scholars Program for New Faculty, January 1986 to December 1987
Visiting Professor, Department of Psychiatry, University of Tennessee, School of Medicine, June 1986
National Alliance for the Mentally Ill (NAMI) National Advisory Board, 1986
Editorial Board, Ways for the Disabled, 1986 to 1988
Chairman of the Board, Dana London Sagalyn Fund, March 1987 to 1988
Chairman, Science Workgroup, Future of Psychiatry Conference, American Psychiatric Association,
March through December 1987
Associate Editor, Journal of Neuropsychiatry and Clinical Neurosciences, 1988 to 1992
Visiting Professor, Pennsylvania State University, Hershey, Pennsylvania, March and April 1988
Visiting Professor, Medical College of Wisconsin, Milwaukee, Wisconsin, June 1988
Juror, Albert and Mary Lasker Medical Research Award, 1989
Co-Chair, Task Force on the Treatment of Depression in Primary Care, American Medical Association,
1989 to 1990
Co-Chair, Public Relations Committee, National Depressive and Manic-Depressive Association, 1989 to
Institute of Medicine Membership Committee, National Academy of Sciences, representing Section 7,
Psychiatry/Neurology; three-year term, 1989-1991
Editorial Board, Advances in Neuropsychiatry & Psychopharmacology, 1989 to 1992
Dialogue Advisory Board, Behavioral Healthcare Tomorrow, 1991
Scientific Advisory Board, Depression and Bipolar Support Alliance, formerly the National Depressive
and Manic-Depressive Association, 1991 to present
Executive Committee, National Depressive and Manic-Depressive Association, 1991-1992
Advisory Board, National Foundation for Brain Research, 1991 to 1995
Editorial Board, Journal of Psychiatric Research, 1991 to 2001
Task Force on Suicide, American College of Neuropsychopharmacology, 1991
International Kraepelin Medal Award Committee, 1992
Charter Member, Academia, Medicinae & Psyhchiatriae Foundation, Inc., 1992
Consultant, Vestermark Award Board, Council on Internal Organization, American Psychiatric
Association, May 1992 to 1993
President’s Development Council, National Alliance for the Mentally Ill, 1992 to 2000
Editorial Advisory Board, Behavioral Healthcare Tomorrow, 1993 to 1999
Member, Board of Directors, Washington Foundation for Psychiatry, September 1994 to 2000
Resident Research Award Board, American Psychiatric Association/Eli Lilly, 1995
Scientific Advisory Committee, Children’s National Medical Center, Children’s Research Institute,
Washington, DC, January 1995 to January 1997
Committee on Relationships With Advocacy Groups, American College of Neuropsychopharmacology
(ACNP), 1995-1998, 2007 to present
Editorial Board, Synapse, 1995 to present
Scientific Advisory Council, American Foundation for Suicide Prevention, 1998 to present
Editorial Board, Understanding Stress, Anxiety and Depression; the International Journal of Mood
Disorders, 1998 to 2000
Editorial Board, Bipolar Disorders: An International Journal of Psychiatry and Neurosciences, 1998 to
Editorial Board, Clinical Approaches in Bipolar Disorders, 2002 to 2004
Member, National Committee to Unite a Divided America, The Center for the Study of the Presidency,
Initiative on Civility and Inclusive Leadership, 2004 to present
Editorial Board, The World Journal of Biological Psychiatry, 2004 to present
Advisory Board, Suicide Awareness Voices of Education (SAVE) 2003 to present
Membership Committee, American Brain Coalition, 2008 to present

Governmental Appointments:

NIMH Clinical Research Review Board, 1970 to January 1981
Coordinator, Clinical Associate Orientation Program, Intramural Research Program, NIMH, 1971
to 1979
NIMH Clinical Investigations Coordinating Committee, including two subcommittees, 1975 to 1981
President, Assembly of Scientists, NIMH-NINCDS, December 1979 to March 1981
Chairman, Scientist Promotion Review Committee, NIMH Intramural Program, January 1980 to
December 1982
Adjunct Professor of Pharmacology, Uniformed Services University of the Health Sciences (USUHS),
School of Medicine, Bethesda, Maryland, January 1980 to 1988
Scholars Advisory Panel of the Scholars in Residence Program, Fogarty International Center, NIH,
July 1984 to June 1988
The Secretary’s Task Force on Suicide, Department of Health and Human Services, Washington, DC,
Scientific Director, The National Depression Awareness, Recognition, and Treatment (D/ART) Program,
NIMH, 1985 Coordinator of AIDS-related activities, Alcohol, Drug Abuse, and Mental Health
Administration, 1986 to 1988
PHS Executive Task Force on AIDS (Chairman, Subgroup on Behavior, Addiction and Neuroscience),
NIH Patent Policy Board, April 1987 to 1992
Committee on NIH Scientific Faculty Proposal, Office of the Secretary, DHHS, May 1987 to 1992
Co-Chair, Public Health Service Work Group on Animal Welfare, 1989-1992
Co-Chair, Public Health Service Science Education Committee, 1989-1992
Federal Coordinating Committee on Science and Technology (FCCSET), Subcommittee on Human
Resources, 1989-1992


Who’s Who in American Colleges and Universities, 1962-1963
Who’s Who in America
A.E.  Bennett Award for Clinical Research, presented by the Society of Biological Psychiatry, May 1970
Psychopharmacology Research Prize, presented by the American Psychological Association, September
Hofheimer Prize for Research, presented by the American Psychiatric Association, May 1971
International Anna-Monika Prize for Research in Depression, June 1971
Taylor Manor Award, 1976
One of only five psychiatrists among Current Contents list of the 1,000 most frequently cited scientific
authors worldwide (top 1/10 of 1 percent); listed as one of the world’s most cited authors (less than
one of 1 percent of all publishing researchers), 2002
Administrator’s Award, ADAMHA, 1977
One of 12 psychiatrists listed in Best Doctors in the US, 1st and 2nd Editions, by John Pekkanen,
Seaview Books, 1979 (and similar books by other publishers)
Public Health Service Superior Service Award, 1980
Senior Scientific Service Bonus, 1981
Senior Executive Service Presidential Rank Award ($10,000) (Meritorious Executive), 1982 (plus other
Federal awards)
Senior Scientific Service Bonus, 1983
Edward A.  Streckar Award, 1983
Senior Scientific Service Bonus, 1984
HHS Nomination for Presidential Rank Award (Distinguished Executive), 1984
University of North Carolina at Chapel Hill Distinguished Alumni Award, 1984
Member, Institute of Medicine, National Academy of Sciences, 1985
Senior Executive Service Rank Award ($20,000) (Distinguished Executive), 1986
Senior Executive Association Professional Development League, Distinguished Executive Service
Award of the Executive Excellence Awards PGM, 1986
DHHS Distinguished Service Award, 1987
Listed in the Town and Country Nationwide Referral Guide to the Best Psychotherapists, March 1988
The First Annual Psychiatrist of the Year Award (Best Teacher in Psychiatry),1989
Service to Science Award from the National Association for Biomedical Research, 1990
Public Service Award from the Federation of American Societies for Experimental Biology, 1990
Fawcett Humanitarian Award from the National Depressive and Manic-Depressive Association (NDMDA),
St. Louis University Alumni Merit Award for Achievement in Biomedical Research, 1990
Association of American Publishers Award for Most Outstanding Book in the Biomedical Sciences, 1990,
for Manic-Depressive Illness, with Kay R.  Jamison (first psychiatry book to receive this award)
The Roy M. Grinker Visiting Professor of Psychiatry, Michael Reese Hospital, Detroit, Michigan, 1990
William R.  McAlpin Research Achievement Award, 1991
Member, Alpha Omega Alpha Honor Medical Society, 1991
National Alliance for the Mentally Ill, Distinguished Service Award, 1994
Mathilde Soloway Award Lecture in the Neurosciences, Foundation for Advanced Education in the
Sciences, Inc., NIH, 1994
Richard Simpson Memorial Award, Incurably Ill for Animal Research (iiFAR), 1994
The Harry Stack Sullivan Award, presented at Sheppard Pratt Hospital, Baltimore, MD, Keynote address
on Scientific Day, March 25, 1995
Unity Award in Media for The Infinite Mind program on “Sleep,” 1998.
The Unity Award in Media, Lincoln University of Missouri, for The Infinite Mind radio program, 1998,
1999 (3)
The National Headliner Award Honors for The Infinite Mind radio program, 1999; second place for The
Infinite Mind program “Perfect Pitch,” 2001; and for “Beyond the Baby Blues: Postpartum Depression
and Psychosis” and “Mental Health in Troubled Times,” 2002  
EDI Awards for Excellence in Media, Easter Seal Society, for The Infinite Mind radio program, 1999 (3)
National Headliner Award for The Infinite Mind program on “Men and Suicide: The Tragedy of Timothy
Hogan,” 1999.
Clarion Award from the Association for Women in Communication for The Infinite Mind program on “Men
and Suicide: The Tragedy of J. Timothy Hogan,” 1999; “The Closing of Haverford State: A Special
Report,” 2000
Nominee, Research! America’s Advocacy Award for The Infinite Mind radio program, 1999
The Nola Maddox Falcone Prize, presented at the Gala Awards Dinner, New York, NY, Keynote address
given at Scientific Dinner, October 14, 1999
Professor ad honorem, School of Medicine of Uruguay, 1999
Who’s Who in Science and Engineering, 2000
Deadline Club Award for “The Closing of Haverford State,” awarded by Sigma Delta Chi, 2000
New York Press Club Best Feature Award for The Infinite Mind, 2000
Epilepsy Foundation Distinguished Journalism Award for The Infinite Mind program on “Epilepsy,” 2000
Gracie Award from American Women in Television and Radio (honorable mention) for The Infinite Mind
program on “Pam’s Story,” 2001
National Headliner Award
International Radio Festival Award from the New York Festivals for The Infinite Mind program on “The
Bipolar Child” 2001  
Gracie Allen Award for “Mental Health in Troubled Times,” 2002
St. Louis University Alumni Award, 2003
National Mental Health Association  Media Award for The Infinite Mind program, “In Any Language: Mental
Health Care for Immigrants,”  2004
Gracie Allen Award for “Domestic Violence” on The Infinite Mind, 2004
Lifetime Achievement Award, The International Review of Bipolar Disorders, 2007
America’s Best Doctors, 2008
Who’s Who in the World, 2009 (in press)


Centennial Lectureship, University of North Carolina, School of Medicine, The first George C.  Ham
Memorial Lecture, University of North Carolina at Chapel Hill, 1984
David C.  Wilson Lecture, University of Virginia at Charlottesville, 1985
Phineas J.  Sparer Distinguished Lectureship in Psychiatry, University of Tennessee, Memphis, June 18-20,
Theodore L.  Dehne, M.D.  Memorial Lecture, presented at the 15th Annual Friends Hospital Clinical
Conference, October 1987
Invited Lecture, Third Vatican International Conference on Longevity and the Quality of Life (“Scientific
Research at the Service of Longevity”), Rome, Italy, 1988
Invited Lecture, Fourth Vatican International Conference on Longevity and the Quality of Life (“Scientific
Research at the Service of Longevity”), Rome, Italy, 1989
The John P.  McGovern Award Lectureship presented at the Annual Meeting of the Association of Academic
Health Centers, Naples, Florida October 5, 1990
The Herbert S.  Ripley Lecture presented at the Department of Psychiatry and Behavioral Sciences,
University of Washington, Seattle, Washington April 24, 1991
Keynote Speaker, International Congress on Depressive Disorders (“Advances in the Understanding and
Treatment of Recurrent Depression and Manic Depressive Illness”) Melbourne, Australia July 1999
The 24th Annual Lebensohn Lecture presented at The Cosmos Club, Washington, D.C. October 23, 1999


American Psychiatric Association (Distinguished Life Fellow, 2001)
American Association for the Advancement of Science
American Philosophical Association (currently inactive)
Washington Psychiatric Society
Society of Biological Psychiatry (currently inactive)
American College of Neuropsychopharmacology (Fellow, 1970)
American Academy of Psychoanalysis (currently inactive)
Society for Neuroscience
Psychiatric Research Society (President 1998-2000)
Collegium Internationale Neuro-Psychopharmacologicum (Fellow, 1972)
American Psychopathological Association
American Society of Clinical Psychopharmacology
Society for Light Treatment and Biological Rhythms
National Committee to Unite a Divided America


The one constant throughout my otherwise varied professional career has been direct patient care.  From 1965 to 1967, I was the primary clinician for inpatients on the Depression Treatment Unit at the NIMH/NIH Clinical Center.  From 1967 to the present, my clinical work has been carried out through a part-time private practice.  In this solo practice setting, I have evaluated and treated hundreds of patients over the years.  Initially, I garnered considerable experience in individual long-term psychodynamic psychotherapy (much of it supervised by training psychoanalysts from the Washington School of Psychiatry), short term cognitive and behavioral psychotherapy, couples therapy, group therapy, and, of course, psychopharmacology.  In recent years I have become more specialized in the evaluation and management (which includes psychotherapy) of patients with treatment-resistant depression and manic-depressive illness.


In May 1994, upon completing 30 years of Federal service, I left my post as Director, NIMH, to establish a Center on Neuroscience, Medical Progress and Society, at The George Washington University in Washington, D.C., where I am Research Professor of Psychiatry.  The Center conducts clinical and services research and policy studies, examining -- from the perspectives of health care, the humanities, philosophy and law -- the impact on society of the behavioral and brain sciences.  Among the initial, specific foci of the Center are issues facing psychiatry, including the impact of managed health care on quality of care, innovation, the doctor-patient relationship and confidentiality;  the stigmatization of mental illness and the anti-science movement’s focus on the behavioral and brain sciences; how concepts of human responsibility and free will can persevere as more is learned about brain function and behavior; and the implications of the Human Genome Project for treating and preventing disorders of behavior.
From 1992 to 1994, I directed the National Institute of Mental Health (NIMH). My return to the Institute permitted me to contribute to the historic reunion of the Institute with the National Institutes of Health (NIH).  Key tasks during the transition included ensuring a continuing, productive association between the research and service sectors of the mental health field, the latter now the responsibility of the new Center for Mental Health Services in the Substance Abuse and Mental Health Services Administration (SAMHSA); serving as a lead HHS spokesman to the mental health field broadly and to the public regarding the aims and benefits of the reorganization; and drawing on my extensive NIMH/NIH experience to facilitate the reintroduction of NIMH programs into the NIH scientific and administrative milieu.
As Director of an Institute with a budget of $613 million (1994) and a staff of more than 1,300, 1,000 of whom are scientists, visiting scientists and support personnel in the Intramural Research Program, I was responsible for further strengthening the mental health research enterprise and for identifying strategies for and overseeing research-based assessments of clinical practice patterns, service system issues, and reimbursement policies germane to mental illness.  Among my priorities were the accelerated implementation of “national plans” focused on schizophrenia, neuroscience, child and adolescent mental disorders, and research on the service need of persons with severe mental disorders; the Treatment Research Initiative; and ensuring that NIMH has continued to play an integral role in health care reform activities.
As Administrator of the Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA), I was responsible for Federal programs pertaining to mental illness, drug abuse, and alcoholism and for providing national leadership in meeting public health needs associated with these disorders.  ADAMHA’s mandate entailed dual responsibilities for supporting and conducting research and for enhancing the Nation’s specialty service systems for mental and addictive disorders.  The Agency’s 1992 budget was $3.2 billion; of this amount, $1.3 billion was for the conduct and support of research and research training, and $1.9 billion supported service system improvement activities.  ADAMHA employed some 2,000 permanent employees, with an additional 400 visiting scientists likely to be working in the Agency’s intramural research laboratories at any given time.  As noted earlier, Congress reorganized ADAMHA in 1992, reuniting its three research institutes -- the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Drug Abuse, and the National Institute of Mental Health -- with the NIH, and creating SAMHSA, dedicated to treatment and prevention-related service activities.
As Director of the NIMH Intramural Research Program (IRP), I was directly responsible for the largest mental health research program in the world.  Comprised of some 20 branches/laboratories distributed across three campuses, the program conducts multidisciplinary research that ranges from the most fundamental neuroscience to clinical research on major mental illness to psychological and social studies of human development.  The IRP, with what was then an annual budget of some $60 million, employed 600 people, of whom just under half are scientists and, additionally, hosted several hundred guest scientists.  Closely linked to its research mission is the program’s role as the nation’s largest single resource for research training in mental health and neuroscience research.  In addition to managing and providing leadership to the NIMH/IRP, I was a member of the NIH Board of Scientific Directors, through which I participated in the formulation of NIH policy governing intramural research.
For three years I served on the HHS Departmental work group assigned to reevaluate and draft regulations for the Protection of Human Subjects of Research.  Prior to this, I represented the Institute in its interactions with the National Commission for the Protection of Human Subjects, giving testimony, preparing draft reports, and generally contributing to policy formulation.


At the Washington School of Psychiatry, I designed and taught an Advanced Seminar in Psychopharmacology, which focused on the psychodynamics of drug administration, including the combined use of psychoactive drugs and analytic therapy.
At The George Washington University Medical Center, I have participated in curriculum planning for psychiatry at the medical student and resident levels.  I also conduct a monthly case conference and serve as a mentor for psychiatric residents taking a research elective. I have given lectures in psychiatry and psychopharmacology to medical students, graduate students, and residents.
I am frequently invited to lecture at universities here and abroad to conduct special teaching programs for practicing physicians, to give public lectures, and to participate in the efforts of the mass media to understand psychiatry and research in neurobiology.  Recent presentations include Columbia University, Cornell University, Duke University, UCLA, University of California San Diego, the Menninger Foundation and Clinic, University of Chicago, University of Pennsylvania, Boston University, Yale University, The Mayo Clinic, Harvard University, University of Naples, Italy, University of Utrecht, the Netherlands, University of San Paulo, Brazil, University of Munich, Germany, the Peking Medical College and the Shanghai First Medical College of the People’s Republic of China, the Karolinska Institute, Stockholm, and many others.
As Co-Chair of the American Medical Association’s Task Force on the Treatment of Depression in Primary Care, I convened a group of specialists in the treatment of depression and leaders of the primary care community to outline a training program in this area, to be run under AMA auspices.
Public addresses include the Smithsonian Institution lecture series, the NIH medicine for the Layman series, the Annual Meetings of the National Mental Health Association, the Philosophical Society of Washington, the National Alliance for the Mentally Ill, and many others.
I was invited by the Chinese Medical Association to lecture at psychiatric facilities in China in June 1980; other members of the seven-person delegation included the Director of NIMH and the President, President-Elect, and Medical Director of the American Psychiatric Association.  I also served as a member of the U.S.-Peoples Republic of China Joint Health Committee in November 1980, and in this capacity I returned to China to participate in the final negotiations and shaping of the U.S.-China Health Agreements.


The challenge of translating -- making our professional and scientific language and concepts both interesting and understandable to the public -- has intrigued me throughout my career.  I have indeed been fortunate that my positions over the years have afforded me ample opportunity to put my belief in the importance of public education into practice.  Not too many years ago, a commitment to public education was clearly against the grain among my scientific colleagues.  I am pleased that that is much less the case today.
From the mid-1980’s on, I worked with various advocacy groups especially the National Alliance for the Mentally Ill (NAMI), the Mental Health Association, and the National Depressive and Manic-Depressive Association (which I helped make into a national organization) in a wide variety of destigmatization efforts.  Early on, I recognized the unique value of pairing patients with professionals in these activities, an approach which has subsequently become widely used.  At one point, I formed a private Foundation to fund depression education programs for college students, an activity that was subsequently incorporated into NAMI.  Many of the educational/advocacy activities in which I was involved were conducted on Capitol Hill for obvious reasons.
I worked with Dr. Kay Jamison in the production of two Moods and Music concerts, the first at UCLA and the second at the Kennedy Center with the National Symphony Orchestra, which became a highly successful television special.  Other activities have included conducting special workshops for reporters at scientific meetings and providing frequent off-the-record background interviews with reporters and writers working on various stories and features.
As host of the award-winning The Infinite Mind since 1998, a one-hour weekly public radio program heard nationwide on over 220 stations, I have had the opportunity to educate the public about the brain, behavioral sciences, and about mental illness.


From 1989 -1992, I represented the Department of Health and Human Services on the Human Resources Subcommittee Federal Coordinating Committee on Science and Technology (FCCSET) and served as founder and Co-Chair of the Public Health Service (PHS) Science Education Committee.   I created and implemented the Science Education Partnership Award (SEPA), a novel grant that supports partnerships among working scientists and primary/secondary school teachers.  The SEPA program was subsequently adopted by the NIH.
In speaking extensively about impediments to scientific literacy, and in advocating programs to improve public understanding of science, and for improved communications by scientists about their work, I worked closely with the National Association of Biology Teachers, the Science Teachers Association and the Biological Sciences Curriculum Study (BSCS).  
I co-directed the NIMH/Library of Congress Decade of the Brain Symposium Series for the Public.  Other relevant activities include the Smithsonian lecture series, the NIH “Medicine for the Layman” Series, the Philosophical Society of Washington and numerous presentations to lay audiences on mental illness and neuroscience research.  I frequently appeared in the print and broadcast media to defend biomedical research, often in a debate format with animal rights advocates.  In association with this, I received formal media training, which has developed my communications skills beyond the level of most of my research colleagues.


1.     Wehr TA, Goodwin FK, eds:  Circadian Rhythms in Psychiatry.  Pacific Grove, CA: The Boxwood
Press, 1983.

2.    Goodwin FK, Jamison KR, eds:  Bipolar Disorders.  In:  RE Hales, AJ Frances, eds:  Psychiatry
Update:  The American Psychiatric Association Annual Review, Vol 6.  Washington, DC:  American
Psychiatric Press, Inc, 1987.

3.    Nerozzi D, Goodwin FK, Costa E, eds:  Advances in Biochemical Psychopharmacology.  Vol. 43.
Hypothalamic Dysfunction in Neuropsychiatric Disorders.  New York:  Raven Press, 1987.

4.     Goodwin FK, Jamison KR:  Manic-Depressive Illness.  New York:  Oxford University Press, 1990.
(Best Medical Book Award from the Association of American Publishers.)

5.     Marneros A, Goodwin FK, eds: Bipolar Disorders: Mixed States, Rapid Cycling, and Atypical Forms.
Cambridge: Cambridge University Press, 2005.

6.     Goodwin FK, Jamison KR:  Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression.
New York:  Oxford University Press, 2007.


1.    Weissbach H, Goodwin FK, Maxwell ES:  The effect of steroids on aldehyde oxidation:  Studies with
indoleacetaldehyde.  Biochem Biophys Acta 49: 384-387, 1961.

2.    Renson J, Goodwin F, Weissbach H, Udenfriend S:  Conversion of tryptophan to 5-hydroxytryptophan
by phenylalanine hydroxylase.  Biochem Biophys Res Comm 6:20-23, 1961.

3.    Hollender MH, Goodwin FK, Fleiss AN, Butz JL, Mariner AS, Kaplan EA, Hunt WL, Pearl NH:  The
compensation problem.  Int Psychiat Clin 2:583-602, 1965.

4.     Hollender MH, Hirsch SJ, Goodwin FK, Kaplan EA, Rubert SL, Watkins ES, Walker L, Steckler PP,
Albaugh JK, Ripich LJ:  Schizophrenia or temporal lobe disorder?  Int Psychiat Clin 2:667-689,

5.     Colburn RW, Goodwin FK, Bunney WE Jr, Davis JM:  Effect of lithium on the uptake of noradrenaline
by synaptosomes.  Nature 215:1395-1397, 1967.

6.    Bunney WE Jr, Goodwin FK, Davis JM, Fawcett JA:  A behavioral-biochemical study of lithium
treatment.  Am J Psychiatry 125:499-512, 1968.

7.    Greenspan K, Goodwin FK, Bunney WE Jr, Durell J:  Lithium ion retention and distribution:  Patterns
during acute mania and normothymia.  Arch Gen Psychiatry 19:664-673, 1968.

8.    Colburn RW, Goodwin FK, Murphy DL, Bunney WE Jr, Davis JM: Quantitative studies of
norepinephrine uptake by synaptosomes.  Biochem Pharmacol 17: 957-964, 1968.

9.    Goodwin FK, Shafritz D, Weissbach H: In vitro polypeptide synthesis in brain.  Arch Biochem Biophys
130:183-190, 1969.

10.   Shafritz D, Goodwin F, Weissbach H:  Inhibition by aminochromes of in vitro polypeptide synthesis
in Escherichia coli.  Arch Biochem Biophys 134:478-485, 1969.

11.   Goodwin FK, Murphy DL, Bunney WE Jr:  Lithium-carbonate treatment in depression and mania:  A
longitudinal double-blind study.  Arch Gen Psychiatry 21: 486-496, 1969.

12.   Bunney WE Jr, Janowsky DW, Goodwin FK, Davis JM, Brodie HKH, Murphy DL, Chase TN:  Effect of
L-dopa on depression.  Lancet i:885-886, 1969.

13.   Goodwin FK, Murphy DL, Bunney WE Jr:  Lithium.  Lancet ii:212-213, 1969.

14.   Murphy DL, Goodwin FK, Bunney WE Jr:  Aldosterone and sodium response to lithium
administration in man.  Lancet  ii:458-461, 1969.

15.   Goodwin FK, Brodie HKH:  The combined use of L-dopa and peripheral decarboxylase inhibitor
(MK 485) in depression.  Ann Intern Med 72:806, 1970.

16.   Goodwin FK, Murphy DL, Brodie HKH, Bunney WE Jr:  L-dopa, catecholamines, and behavior:  A
clinical and biochemical study in depressed patients. Biol Psychiatry 2:341-366, 1970.  (AE Bennett
Prize Paper)

17.    Bunney WE Jr, Murphy DL, Brodie HKH, Goodwin FK:  L-dopa in depressed patients.  Lancet i:352,

18.    Goodwin FK, Brodie HKH, Murphy DL, Bunney WE Jr:  Administration of a peripheral decarboxylase
inhibitor with L-dopa to depressed patients.  Lancet i:908-911, 1970.

19.    Paul MI, Cramer H, Goodwin FK:  Urinary cyclic AMP in affective illness. Lancet i:996, 1970.

20.    Bunney WE Jr, Murphy DL, Goodwin FK, Borge GF:  The switch process from depression to mania:
Relationship to drugs which alter brain amines.  Lancet i:1022-1027, 1970.

21.    Tamarkin NR, Goodwin FK, Axelrod J:  Rapid elevation of biogenic amine metabolites in human CSF
following probenecid.  Life Sci 9:1397-1408, 1970.

22.   Fram DH, Murphy DL, Goodwin FK, Brodie HKH, Bunney WE Jr, Snyder F: L-dopa and sleep in
depressed patients.  Psychophysiology 7:316-317, 1970.

23.   Brodie HKH, Murphy DL, Goodwin FK, Bunney WE Jr:  Alpha-methyl-para-tyrosine in affective
illness.  In:  O Vinar, Z Voltava, PB Bradley, eds: Advances in Neuropsychopharmacology:
Proceedings of the 7th Congress of the Collegium Internationale Neuro-Psychopharmacologicum.
Amsterdam: North-Holland, 1971.  pp 141-144.

24.   Bunney WE Jr, Brodie HKH, Murphy DL, Goodwin FK:  Studies of alpha-methyl-para-tyrosine,
L-dopa, and L-tryptophan in depression and mania. Am J Psychiatry 127:872-881, 1971.

25.   Murphy DL, Goodwin FK, Bunney WE Jr:  Leucocytosis during lithium treatment. Am J Psychiatry
127:1559-1561, 1971.

26.   Buchsbaum M, Goodwin F, Murphy D, Borge G:  AER in affective disorders. Am J Psychiatry
128:19-25, 1971.

27.   Paul MI, Cramer H, Goodwin FK: Urinary cyclic AMP in depression and mania:  Effects of levodopa
and lithium carbonate.  Arch Gen Psychiatry 24:327-333, 1971.

28.   Borge GF, Buchsbaum M, Goodwin F, Murphy D, Silverman J: Neuropsychological correlates of
affective disorders.  Arch Gen Psychiatry 24:501-504, 1971.

29.   Gershon ES, Dunner DL, Goodwin FK: Toward a biology of affective disorders: Genetic contributions.
Arch Gen Psychiatry 25:1-15, 1971.

30.   Dunner DL, Cohn CK, Gershon ES, Goodwin FK:  Differential catechol-O-methyl-transferase activity
in unipolar and bipolar affective illness.   Arch Gen Psychiatry 25:348-353, 1971.

31.   Gershon ES, Bunney WE Jr, Goodwin FK, Murphy DL, Dunner DL, Henry GM: Catecholamines and
affective illness:  Studies with L-dopa and alpha-methyl-para-tyrosine.  In:  BT Ho, WM McIsaac,
eds:  Brain Chemistry and Mental Disease. Vol.  1.  New York:  Plenum Press, 1971.  pp 135-161.

32.  Dunner DL, Brodie HKH, Goodwin FK:  Plasma dopa response to levodopa administration in man:
Effects of a peripheral decarboxylase inhibitor.  Clin Pharmacol Ther 12:212-217, 1971.

33.  Brodie HK, Murphy DL, Goodwin FK, Bunney WE Jr:  Catecholamines and mania:  The effect of
alpha-methyl-para-tyrosine on manic behavior and catecholamine metabolism.  Clin Pharmacol Ther
12:218-224, 1971.

34.  Goodwin FK, Murphy DL, Brodie HKH, Bunney WE Jr:  Levodopa:  Alterations in behavior.  Clin
Pharmacol Ther 12:383-396, 1971.

35.  Murphy DL, Goodwin FK, Bunney WE Jr:  Clinical and pharmacological investigations of the
psychobiology of the affective disorders.  Int Pharmacopsychiatry 6:137-146, 1971.

36.  Goodwin FK:  Psychiatric side effects of levodopa in man.  JAMA 218:1915-1920, 1971.

37.  Goodwin FK, Dunner DL, Gershon ES:  Effect of L-dopa treatment on brain serotonin metabolism in
depressed patients.  Life Sci 10:751-759, 1971.

38.   Murphy DL, Brodie HK, Goodwin FK, Bunney WE Jr:  Regular induction of hypomania by L-dopa in
“bipolar” manic-depressive patients.  Nature 229:135-136, 1971.

39.   Goodwin FK, Bunney WE Jr:  Depressions following reserpine: A reevaluation. Semin Psychiatry
3:435-448, 1971.    

40.   Goodwin FK:  Behavioral effects of L-dopa in man.  Semin Psychiatry 3:477-492, 1971.

41.   Dunner DL, Goodwin FK, Gershon ES, Murphy DL, Bunney WE Jr:  Excretion of 17-OCHS in unipolar
and bipolar depressed patients.  Arch Gen Psychiatry 26:360-363, 1972.

42.   Dunner DL, Goodwin FK:  Effect of L-tryptophan on brain serotonin metabolism in depressed
patients.  Arch Gen Psychiatry 26:364-366, 1972.

43.   Bunney WE Jr, Murphy DL, Goodwin FK, Borge GF:  The “switch process” in manic-depressive
illness:  I.  A systematic study of sequential behavior changes. Arch Gen Psychiatry 27:295-302,

44.  Bunney WE Jr, Goodwin FK, Murphy DL, House KM, Gordon EK:  The “switch process” in manic-
depressive illness:  II. Relationship to catecholamines, REM sleep, and drugs.  Arch Gen Psychiatry
27:304-309, 1972.

45.  Bunney WE Jr, Goodwin FK, Murphy DL: The “switch process” in manic-depressive illness:  III.
Theoretical implications.  Arch Gen Psychiatry 27:312-317, 1972.

46.  Goodwin FK, Murphy DL, Dunner DL, Bunney WE Jr:  Lithium response in unipolar versus bipolar
depression.  Am J Psychiatry 129:44-47, 1972.

47.   Kotin J, Goodwin FK:  Depression during mania:  Clinical observations and theoretical implications.
Am J Psychiatry 129:679-686, 1972.

48.   Goodwin FK, Bunney WE Jr:  The biology of bipolar affective illness: Studies with L-dopa and alpha-
methyl-para-tyrosine.  In:  S Gershon, chair, 10th Annual American College of
Neuropsychopharmacology symposium:  Amines and Affective Disorders.  Psychopharmacol Bull
8(4):33-34, 1972.

49.  Goodwin FK, Post RM:  Problems in the study of amine turnover in man-the probenecid technique.
In:  WE Bunney Jr, chair, 10th Annual American College of Neuropsychopharmacology symposium:
Methods for the Study of Amine Function in Man.  Psychopharmacol Bull 8(4):12-13, 1972.

50.   Post RM, Kotin J, Matzen M, Jones CC, Goodwin FK:  Effect of serum from depressed and manic
patients on maze behavior of rats.  Experientia 28:1471-1472, 1972.

51.   Murphy DL, Goodwin FK, Bunney WE Jr:  A reevaluation of biogenic amines in manic and depressive
states.  Hosp Prac 7:85-92, 1972.

52.   Bunney WE Jr, Gershon ES, Murphy DL, Goodwin FK:  Psychobiological and pharmacological studies
of manic-depressive illness.  J Psychiatr Res 9:207-226, 1972.

53.   Cramer H, Goodwin FK, Post RM, Bunney WE Jr:  Effects of probenecid and exercise on
cerebrospinal-fluid cyclic A.M.P. in affective illness. Lancet i:1346-    1347, 1972.

54.   Ebert MH, Post RM, Goodwin FK:  Effect of physical activity on urinary MHPG excretion in depressed
patients.  Lancet ii:766, 1972.

55.   Bunney WE Jr, Goodwin FK, Murphy DL:  Some current psychobiological studies of the effects of
L-dopa in depressive and manic-depressive patients.  In: S Malitz, ed: L-dopa and Behavior.  New
York:  Raven Press, 1972.  pp 87-102.

56.   Goodwin FK, Ebert MH, Bunney WE Jr:  Mental effects of reserpine in man: A review.  In:  RI Shader,
ed: Psychiatric Complications of Medical Drugs. New York: Raven Press, 1972.  pp 73-101.

57.   Goodwin FK:  Behavioral effects of L-dopa in man.  In:  RI Shader, ed: Psychiatric Complications of
Medical Drugs.  New York:  Raven Press, 1972. pp 149-174.

58.   Murphy DL, Goodwin FK, Bunney WE Jr:  Electrolyte changes in the affective disorders:  Problems of
specificity and significance.  In:  TA Williams, MM Katz, JA Shield, eds:  Recent Advances in the
Psychobiology of the Depressive Illnesses.  Washington, DC:  US Government Printing Office,
1972.  pp 59-70.

59.   Post RM, Kotin J, Goodwin FK, Gordon EK:  Psychomotor activity and cerebrospinal fluid amine
metabolites in affective illness.  Am J Psychiatry 130:67-72, 1973.

60.   Goodwin FK, Post RM, Dunner DL, Gordon EK: Cerebrospinal fluid amine metabolites in affective
illness:  The probenecid technique.  Am J Psychiatry 130:73-79, 1973.

61.   Murphy DL, Goodwin FK, Brodie HKH, Bunney WE Jr:  L-dopa, dopamine, and hypomania.  Am J
Psychiatry 130: 79-82, 1973.

62.   Kotin J, Post RM, Goodwin FK:  Drug treatment of depressed patients referred for hospitalization.
Am J Psychiatry 130:1139-1141, 1973.

63.   Carlson GA, Goodwin FK:  The stages of mania: A longitudinal analysis of the manic episode.  Arch
Gen Psychiatry 28:221-228, 1973.

64.  Kotin J, Post RM, Goodwin FK:  Delta-9-tetrahydrocannabinol in depressed patients.  Arch Gen
Psychiatry 28:345-348, 1973.

65.  Gershon ES, Dunner DL, Sturt L, Goodwin FK:  Assortative mating in the affective disorders.  Biol
Psychiatry 7:63-74, 1973.

66.  Buchsbaum M, Landau S, Murphy DL, Goodwin FK:  Average evoked response in bipolar and unipolar
affective disorders:  Relationship to sex, age of onset, and monoamine oxidase.  Biol Psychiatry 7:
199-212, 1973.

67.  Post RM, Goodwin FK:  Simulated behavior states:  An approach to specificity in psychobiological
research.  (AE Bennett Award Paper.) Biol Psychiatry 7:237-254, 1973.

68.  Gillin JC, Post RM, Wyatt RJ, Goodwin FK, Snyder F, Bunney WE Jr:  REM inhibitory effect of L-dopa
infusion during human sleep.  Electroencephalogr Clin Neurophysiol 35:181-186, 1973.

69.  Goodwin FK, Sack RL:  Affective disorders:  The catecholamine hypothesis revisited.  In:  E Usdin, SH
Snyder eds:  Frontiers in Catecholamine Research.  New York:  Pergamon Press, 1973. pp

70.  Goodwin FK, Ebert M:  Lithium in mania:  Clinical trials and controlled studies. In: S Gershon, B
Shopsin, eds:  Lithium:  Its Role in Psychiatric Research and Treatment.  New York:  Plenum Press,
1973.  pp 237-252.

71.   Gordon EK, Oliver J, Goodwin FK, Chase T, Post RM:  Effect of probenecid on free 3-methoxy-
4-hydroxyphenylethylene glycol (MHPG) and its sulfate in human cerebrospinal fluid.
Neuropharmacology 12:391-396, 1973.

72.    Goodwin FK, Bunney WE Jr:  A psychobiological approach to affective illness.         Psychiatr Ann 3:19-53, 1973.

73.    Post RM, Gordon EK, Goodwin FK, Bunney WE Jr:  Central norepinephrine
metabolism in affective illness:  MHPG in the cerebrospinal fluid.  Science     179:1002-1003, 1973.

74.    Post RM, Goodwin FK, Gordon E, Watkin DM:  Amine metabolites in human
cerebrospinal fluid:  Effects of cord transection and spinal fluid block.  Science     179:897-899, 1973.

75.    Goodwin FK, Bunney WE Jr:  Psychobiological aspects of stress and
affective illness.  In: JP Scott, EC Senay, eds:  Separation and Depression.
Washington, DC:  American Association for the Advancement of Science,
1973.  pp 91-112.

76.    Goodwin FK, Post RM:  The use of probenecid in high doses for the estimation
of central serotonin turnover in affective illness and addicts on methadone. In: J        Barchas, E Usdin, eds:  Serotonin and Behavior.  New York: Academic Press,     1973.  pp 469-480.

77.    Goodwin FK, Post RM:  Brain serotonin, affective illness and antidepressant     drugs:  Cerebrospinal fluid studies with probenecid.  In : E Costa, GL Gessa, M     Sandler, eds:  Advances in Biochemical Psychopharmacology.  Vol 11:  
Serotonin - New Vistas:  Biochemistry and Behavioral and Clinical Studies.  
New York:  Raven Press, 1974.  pp 341-355.

78.    Ablon SL, Goodwin FK:  High frequency of dysphoric reactions to
tetrahydrocannabinol among depressed patients.  Am J Psychiatry 131:448-453,     1974.

79.    Post RM, Kotin J, Goodwin FK:  The effects of cocaine on depressed patients.
Am J Psychiatry 131:511-517, 1974.

80.    Ablon SL, Carlson GA, Goodwin FK:  Ego defense patterns in manic-depressive     illness.  Am J Psychiatry  131:803-807, 1974.

81.      Post RM, Goodwin FK:  Effects of Amitriptyline and imipramine on amine
metabolites in the cerebrospinal fluid of depressed patients.  Arch Gen
Psychiatry 30:234-239, 1974.

82.    Sack RL, Goodwin FK:  Inhibition of dopamine-beta-hydroxylase in manic        patients:  A clinical trial with fusaric acid.  Arch Gen Psychiatry 31:649-654,     1974.

83.    Beckmann H, Jones C, Goodwin FK:  Unterschiedliche Ausscheidung von 3-
Methoxy-4-hydroxyphenylglycol im Urin und Ansprechen auf trizyklische
Antidepressiva.  Arzneimittel-Forschung 24:1010-1012, 1974.

84.    Goodwin FK, Sack RL:  Behavioral effects of new dopamine-beta-hydroxylase
inhibitor (fusaric acid) in man.  J Psychiatr Res 11:211-217, 1974.

85.    Carman JS, Post RM, Teplitz TA, Goodwin FK:  Letter:  Divalent cations in
predicting antidepressant response to lithium.  Lancet ii:1454, 1974.

86.    Goodwin  FK, Sack RL:  Central dopamine function in affective illness:  
Evidence from precursors, enzyme inhibitors, and studies of central dopamine
turnover.  In: E Usdin:  Neuropsychopharmacology of Monoamines and Their Regulatory Enzymes.  New York:  Raven Press, 1974.  pp 261-279.

87.    Goodwin FK:  Summary.  In:  IS Forrest, CJ Carr, E Usdin, eds: Phenothiazines        and Structurally Related Drugs.  New York:  Raven Press, 1974. pp 799-804.

88.    Goodwin FK:  On the biology of depression.  In:  RJ Friedman, MM Katz, eds:
The Psychology of Depression:  Contemporary Theory and Research.    
Washington, DC:  VH Winston & Sons, 1974.  pp 240-251.

89.    Murphy DL, Baker M, Goodwin FK, Miller H, Kotin J, Bunney WE Jr:  L-
tryptophan in affective disorders:  Indoleamine changes and differential clinical        effects.  Psychopharmacologia (Berlin) 34:11-20, 1974.

90.    Post RM, Gillan JC, Wyatt RJ, Goodwin FK:  The effect of orally administered
cocaine on sleep of depressed patients.  Psychopharmacologia (Berlin) 37:59-66,     1974.

91.    Goodwin FK, Murphy DL:  Biological factors in the affective disorders and        schizophrenia.  In:  M Gordon, ed:  Psychopharmacological Agents.  Vol 3.
New York:  Academic Press, 1974.  pp 9-37.

92.    Post RM, Goodwin FK:  Estimation of brain amine metabolism in affective
illness:  Cerebrospinal fluid studies utilizing probenecid.  Psychother Psychosom 23:142-    158, 1974.

93.    Murphy DL, Goodwin FK, Bunney WE Jr:  The psychobiology of mania.  In:  D
Hamburg, HKH Brodie, eds:  American Handbook of Psychiatry.  Vol.  6.  New
York:  Basic Books, 1975.  pp 502-532.

94.    Goodwin FK, Murphy DL:  Biological factors in the major psychoses.  Annual
Reports in Medicinal Chemistry 10:  39-50, 1975.

95.    Beckmann K, Goodwin FK:  Antidepressant response to tricyclics and urinary
MHPG in unipolar patients:  Clinical response to imipramine or amitriptyline.
Arch Gen Psychiatry 32:17-21, 1975.

96.     Post RM, Fink E, Carpenter WT, Goodwin FK:  Cerebrospinal fluid amine
metabolites in acute schizophrenia.  Arch Gen Psychiatry 32:1063-1069, 1975.

97.    Goodwin FK, Post RM:  Studies of amine metabolites in affective illness and in
schizophrenia:  A comparative analysis.  In:  DX Freedman, ed:  Biology of the        Major Psychoses:  A Comparative Analysis.  Research Publications: Association     for Research in Nervous and Mental Disease.  Vol. 54.  New York: Raven Press,     1975.  pp 299-332.

98.    Jimerson DC, Gordon EK, Post RM, Goodwin FK:  Central noradrenergic
function in man:  Vanillylmandelic acid in CSF.  Brain Res 99:434-439, 1975.

99.    Goodwin FK, Sack RL:  Behavioral effects of a new dopamine-beta-hydroxylase
inhibitor (fusaric acid) in man.  In:  SW Matthysse, SS Kety, eds, Catecholamines and Schizophrenia.  New York:  Pergamon Press, 1975.  pp 211-217.

100.    Belmaker R, Beckmann H, Goodwin F, Murphy D, Pollin W, Buchsbaum M,
Wyatt R, Ciaranello R, Lamprecht F:  Relationships between platelet and plasma
monoamine oxidase, plasma dopamine-beta-hydroxylase, and urinary 3-methoxy-4-hydroxyphenylglycol.  Life Sci 16: 273-280, 1975.

101.    Goodwin FK, Post RM, Sack RL:  Clinical evidence for neurochemical adaptation to psychotropic drugs.  In:  AJ Mandell, ed:  Neurobiological Mechanisms of Adaptation and Behavior.  New York:  Raven Press, 1975.  pp 33-45.

102.    Claeys M, Muscettola G, Goodwin FK, Markey SP:  Simultaneous measurement
of plasma levels of imipramine and desipramine in patients with primary affective disorders.  In: ER Klein, DP Klein, eds:  Proceedings of the Second International Conference on Stable Isotopes.  Springfield, VA: National Technical Information Service, US Department of Commerce 1975.  pp 198-207.

103.    Goodwin FK, Post RM, Jimerson D:  Studies of CSF amine metabolites in        affective illness and in schizophrenia.  M Airaksinen, ed:  Proceedings of the
Sixth International Congress of Pharmacology:  Vol 3.  CNS and Behavioral        Pharmacology.  Oxford:  Pergamon Press, 1975.  pp 285-297.

104.    Post RM, Goodwin FK:  Studies of cerebrospinal fluid amine metabolites in         depressed patients:  Conceptual problems and theoretical implications.  In:  J     Mendels, ed:  The Psychobiology of Depression.  New York:  Spectrum     Publications, New York, 1975.  pp 47-67.

105.    Beckmann H, St.-Laurent J, Goodwin FK:  The effect of lithium on urinary
MHPG in unipolar and bipolar depressed patients.  Psychopharmacologia
(Berlin) 42:277-282, 1975.

106.    Lipton MA, Goodwin FK:  A controlled study of thyrotropin releasing hormone
in hospitalized depressed patients.  Psychopharmacol Bull 11:8-29, 1975.

107.    Goodwin FK, Post RM:  Cerebrospinal fluid amine metabolites in affective
illness and schizophrenia: Clinical and pharmacological studies. Psychopharmocol Commun 1:641-653, 1975.

108.    Post RM, Goodwin FK:  Time-dependent effects of phenothiazines on dopamine
turnover in psychiatric patients.  Science 190:488-489, 1975.

109.    Carman JS, Post RM, Buswell R, Goodwin FK:  Negative effects of melatonin
on depression.  Am J Psychiatry 133:1181-1186, 1976.

110.    Kopin IJ, Kaufman S, Viveros H, Jacobowitz D, Lake CR, Ziegler MG,
Lovenberg W, Goodwin FK:  Dopamine-beta-hydroxylase:  Basic and clinical
studies.  Ann Int Med 85:211-223, 1976.

111.    Post RM, Kotin J, Goodwin FK:  Effects of sleep deprivation on mood and
central amine metabolism in depressed patients.  Arch Gen Psychiatry 33:627-632, 1976.

112.    Dunner DL, Gershon ES, Goodwin FK:  Heritable factors in the severity of        affective illness.  Biol Psychiatry 11:31-42, 1976.

113.    Beckmann H, van Kammen DP, Goodwin FK, Murphy DL:  Urinary excretion
of 3-methoxy-4-hydroxyphenylglycol in depressed patients: Modifications by
amphetamine and lithium.  Biol Psychiatry 11:377-387, 1976.

114.    St.-Laurent J, Roizen MF, Beckmann H, Miliaressis E, Goodwin FK, Jacobowitz     DM:  Neurochemical changes in discrete areas of the rat brain after self-        stimulation from the area ventralis tegmenti.  In:  A Wanquier, ET Rolls, eds:      Brain-Stimulation Reward.  Amsterdam:  North-Holland Publishing Company,     1976.  pp 283-289.

115.    Chodoff P,